CADTH | Evidence Driven
CADTH | Evidence Driven

exagamglogene autotemcel

Details

Generic Name:
exagamglogene autotemcel
Project Status:
Pending
Therapeutic Area:
Sickle cell disease (SCD)
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SG0830-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Sickle cell disease in patients 12 and older with recurrent vaso-occlusive crises (VOCs).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Sickle cell disease in patients 12 and older with recurrent vaso-occlusive crises (VOCs).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : March 19, 2024